Clinical Trial

Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 16, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-03-31
notable Primary completion pushed: 2026-05 -> 2026-06 2026-03-31
minor Completion pushed: 2026-05 -> 2026-06 2026-03-31
Trial Details
NCT Number NCT07419347
Lead Sponsor AbbVie
Conditions Hepatitis C Virus (HCV)
Enrollment 2,000 participants
Start Date 2026-02-27
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-16